Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageBiogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer’s disease and launched the first approved treatment to target a genetic cause of ALS.
In the company’s own words · 10-K filed Feb 6, 2026 · SEC EDGAR
Business segments
Jun 2026 · $2.95BThe company’s own SEC segment disclosure.
- Royalty Attributed To OCREVUS$381.4M13%
- Rare Disease Product$294.9M10%
- Tysabri Product$270.5M9%
- Product And Service Other$242.4M8%
- Contract Manufacturing And Other$232.4M8%
- Fumarate$204.4M7%
- Other (18)$1.33B45%
Biogen (BIIB) reported revenue of $2.48B in Q1 2026 (quarter ended Mar 31, 2026), up 1.9% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $320M (13% of revenue). For the full year FY2025, revenue was $9.89B (+2.2% year on year) and net income $1.29B. Its largest product in Jun 2026 was Royalty Attributed To OCREVUS at $381M, 13% of the disclosed total, just ahead of Rare Disease Product at 10.0%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - General
The closest names by size in the same industry